Skip to Main Content

Following a two-year investigation, Roche (RHHBY) was fined $14 million by antitrust authorities in Romania for using different tactics to impede competition to a pair of its cancer medicines, the latest effort by European governments to crack down on anti-competitive practices.

In one instance, Roche allegedly monopolized the market for Rituxan and Herceptin by undercutting rival bidders in auctions that were held to supply a national program for cancer medicines as well as hospitals. Specifically, the drug maker sold the medicines at higher wholesale prices to two distributors, which were also bidding, than to its own subsidiary, making it difficult for these companies to compete.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!